NovaBridge Biosciences is a global biotechnology platform company that identifies and develops novel therapeutics through strategic partnerships and specialized subsidiary entities, operating across immuno-oncology and retinal disease areas. The company's pipeline includes three clinical-stage immuno-oncology programs—givastomig (a CLDN18.2 and 4-1BB bispecific antibody for gastric and gastrointestinal cancers), uliledlimab (a CD73 neutralizing antibody for advanced non-small-cell lung cancer), and ragistomig (a PD-L1 and 4-1BB bispecific antibody)—alongside VIS-101, a VEGF-A and ANG-2 bispecific antibody developed through subsidiary Visara for wet age-related macular degeneration and diabetic macular edema. The company generates value through milestone payments and upfront fees from collaborative arrangements with global partners, co-development agreements that share commercialization rights, and acquisitions of therapeutic assets and platform technologies that expand its pipeline and capabilities.